Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical ... - Ethiopian Review PDF Print
Ethiopian Review... open-label study of two dose levels of IMO-2055 in patients with metastatic or recurrent renal cell carcinoma”, are being made by Timothy Kuzel,

... read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.